Abstract
First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change in therapy is a response to both disease reemergence and increasing antimonial failure.
MeSH terms
-
Adolescent
-
Adult
-
Amphotericin B / therapeutic use*
-
Animals
-
Antiprotozoal Agents / therapeutic use*
-
Child
-
Drug Combinations
-
Drug Therapy / trends
-
Humans
-
Italy
-
Leishmania infantum / growth & development*
-
Leishmania infantum / metabolism
-
Leishmaniasis, Visceral / drug therapy*
-
Leishmaniasis, Visceral / parasitology
-
Meglumine / therapeutic use*
-
Meglumine Antimoniate
-
Organometallic Compounds / therapeutic use*
-
Phosphatidylcholines / therapeutic use*
-
Phosphatidylglycerols / therapeutic use*
-
Retrospective Studies
Substances
-
Antiprotozoal Agents
-
Drug Combinations
-
Organometallic Compounds
-
Phosphatidylcholines
-
Phosphatidylglycerols
-
liposomal amphotericin B
-
Meglumine
-
Meglumine Antimoniate
-
Amphotericin B